<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic stem cell transplantation is a potentially curative treatment for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Transplants are clearly indicated in patients with intermediate-2 and high risk disease; there is controversy regarding when transplantation should be performed in patients with low and intermediate-1 risk disease </plain></SENT>
<SENT sid="2" pm="."><plain>Most patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are over age 65 and Medicare has recently provisionally approved transplants, but only when performed as part of a comparative clinical trial which still must be finalized </plain></SENT>
<SENT sid="3" pm="."><plain>Nonmyeloablative preparative regimens allow treatment of older patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and novel approaches are under evaluation to reduce the risk of relapse and treatment related morbidity and mortality </plain></SENT>
</text></document>